Hemispherx BioPharma, Inc (NYSEAMERICAN:HEB – Get Free Report) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.00 and traded as high as $0.26. Hemispherx BioPharma shares last traded at $0.25, with a volume of 149,044 shares trading hands.
Hemispherx BioPharma Trading Down 3.3 %
Hemispherx BioPharma Company Profile
Hemispherx Biopharma, Inc, a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS).
Further Reading
- Five stocks we like better than Hemispherx BioPharma
- Retail Stocks Investing, Explained
- Survey Reveals: America’s Most Coveted Businesses in 2024
- How to Invest in the FAANG Stocks
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- What Are Growth Stocks and Investing in Them
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Hemispherx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemispherx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.
